Previous 10 | Next 10 |
Esperion Therapeutics press release ( NASDAQ: ESPR ): Q2 GAAP EPS of -$1.05 misses by $0.13 . Revenue of $18.84M (-53.7% Y/Y) beats by $0.22M . The decrease is due to a one-time milestone payment from our collaboration partners in the second quarter of 2021, pa...
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid a...
Esperion Therapeutics ( NASDAQ: ESPR ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. EPS Estimate is -$0.92 (+44.9% Y/Y) and the consensus Revenue Estimate is $18.62M (-54.2% Y/Y). has beaten EPS estimates 50% of the time and has ...
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent a diverse group of internationally renowned experts who will bring a depth and breadth of...
ANN ARBOR, Mich., July 12, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, August 2, 2022. Following the release, company management will host a webcast at ...
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced findings from ...
ANN ARBOR, Mich., June 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies Global Healthcare Conference on June 8 th , 2022. A live audio webcast can be access...
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholde...
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s research into efficacy of bempedoic acid in patients wi...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the follow...
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website . JMP Securities’ Life Sc...
ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial ...